Propensity‐Matched Five‐Year Cardiac Resynchronization Therapy Outcomes in Sarcoidosis With Heart Failure
Journal of Cardiovascular Electrophysiology · 2026
DOI: 10.1111/jce.70204 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2026. Verfasst von Yong Hao Yeo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine/Pediatrics, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA. Hauptthemen laut MEDLINE: Heart Failure, Cardiac Resynchronization Therapy, Sarcoidosis, Ventricular Function, Left. Die Arbeit nennt 20 Literaturangaben. Gefördert von: The authors received no specific funding for this study..
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Introduction
Cardiac resynchronization therapy (CRT) improves clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, data on its efficacy in patients with sarcoidosis and HFrEF are limited.
Methods
Using the TriNetX network, we identified patients with sarcoidosis, heart failure with a left ventricular ejection fraction (LVEF) below 35%, and either left bundle branch block (LBBB) or prolonged QRS duration ( > 150 ms) between 2014 and 2019. Patients were categorized into two cohorts: (1) those who received CRT and (2) those who received an ICD‐only implant. Five‐year outcomes included all‐cause mortality, all‐cause hospitalization, heart failure exacerbation, and the proportion of patients with improvement in LVEF to greater than 40% and greater than 50%.
Results
Out of 245 eligible patients, we identified a cohort of 87 patients (mean age 62.6 ± 9.5 years) who received CRT and 87 patients (mean age 62.1 ± 11.1 years) who received ICD‐only implant, with similar propensity scores, and included them in a comparative analysis. At 5‐year follow‐up, the CRT group demonstrated outcomes comparable to the ICD‐only implant group for all‐cause mortality (14.9% vs. 20.7%; HR 0.63; 95% CI 0.31–1.28; p = 0.19), all‐cause hospitalization (83.9% vs. 77.0%; HR 1.24; 95% CI 0.89–1.73; p = 0.19), and heart failure exacerbation (28.7% vs. 28.7%; HR 0.90; 95% CI 0.52–1.57; p = 0.72). The proportion of patients with improvement in LVEF to greater than 40% and greater than 50% was also similar in both groups (LVEF > 40%, 43.7% vs. 33.3%; HR 1.30; 95% CI 0.80–2.10; p = 0.29; LVEF > 50%, 31.0% vs. 17.2%; HR 1.72; 95% CI 0.92–3.24; p = 0.09).
Conclusion
CRT implantation had similar long‐term outcomes compared to ICD‐only implantation in patients with sarcoidosis and HFrEF, particularly all‐cause mortality, all‐cause hospitalization, heart failure exacerbation, and the proportion of patients with improvement in LVEF to greater than 40% and greater than 50%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine/Pediatrics, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.
- Department of Medicine, One Brooklyn Health System/Interfaith Medical Center, Brooklyn, New York, USA.
- Department of Medicine, Cleveland Clinic Fairview Hospital, Cleveland, Ohio, USA.
- Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona, USA.
- Department of Medicine, New York Medical College at St. Michael Medical Center, Newark, New Jersey, USA.
- Department of Medicine, SUNY Upstate Medical University, Syracuse, New York, USA.
ORCID-Profile: Yong Hao Yeo, Tze Ern Ong, Min Choon Tan, Hicham El-Masry, Abhishek Deshmukh, Christopher V DeSimone
Förderung
- The authors received no specific funding for this study.
Zitieren
APA
Yeo, Y. H., Ong, T. E., Vignarajah, A., Tan, M. C., Vigneswaramoorthy, N., Scott, L., El-Masry, H., Sorajja, D., Deshmukh, A., DeSimone, C. V., & Lee, J. Z. (2026). Propensity‐Matched Five‐Year Cardiac Resynchronization Therapy Outcomes in Sarcoidosis With Heart Failure. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.70204
Vancouver
Yeo YH, Ong TE, Vignarajah A, Tan MC, Vigneswaramoorthy N, Scott L, et al. Propensity‐Matched Five‐Year Cardiac Resynchronization Therapy Outcomes in Sarcoidosis With Heart Failure. Journal of Cardiovascular Electrophysiology. 2026. doi:10.1111/jce.70204
BibTeX
@article{Yeo2026,
author = {Yeo, Yong Hao and Ong, Tze Ern and Vignarajah, Aravinthan and Tan, Min Choon and Vigneswaramoorthy, Nishanthi and Scott, Luis and El-Masry, Hicham and Sorajja, Dan and Deshmukh, Abhishek and DeSimone, Christopher V and Lee, Justin Z},
title = {Propensity‐Matched Five‐Year Cardiac Resynchronization Therapy Outcomes in Sarcoidosis With Heart Failure},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2026},
doi = {10.1111/jce.70204}
}
EUVIMED